Search Results

Riverain Technologies, the pioneer of Clear Visual Intelligence™ for chest imaging interpretation, was selected by the Veterans Health Administration to provide its unique imaging interpretation solution, ClearRead™ CT, to the Veteran Affair’s Lung Precision Oncology Program.

Riverain Technologies ™ Expands Partnerships for Automated, Efficient End-to-End Lung Cancer Screening Capabilities.

Riverain Technologies™, a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, will showcase its solutions and enhancements at the 107th Annual Radiological Society of North America (RSNA) meeting.

• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.

After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.